Core Viewpoint - 博腾股份 has experienced a decline in stock price recently, despite a significant increase in its stock price year-to-date, indicating potential volatility in the market [1][2]. Financial Performance - For the period from January to September 2025, 博腾股份 reported revenue of 2.544 billion yuan, representing a year-on-year growth of 19.72% [2]. - The net profit attributable to shareholders for the same period was 79.9154 million yuan, showing a substantial increase of 138.71% year-on-year [2]. Stock Market Activity - As of November 19, 博腾股份's stock price was 23.73 yuan per share, with a market capitalization of 12.896 billion yuan [1]. - The stock has seen a year-to-date increase of 50.48%, but has declined by 2.83% over the last five trading days and 3.18% over the last twenty days [1]. Shareholder Information - As of November 10, 博腾股份 had 46,700 shareholders, a decrease of 2.23% from the previous period [2]. - The average number of circulating shares per shareholder increased by 1.96% to 10,674 shares [2]. Dividend Distribution - 博腾股份 has distributed a total of 1.193 billion yuan in dividends since its A-share listing, with 866 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder was Hong Kong Central Clearing Limited, holding 23.9776 million shares, an increase of 13.2187 million shares from the previous period [3]. - New institutional shareholders include 华安聚优精选混合, which holds 3.7775 million shares [3].

Core Viewpoint - Boten Co., Ltd. experienced a stock price decline of 2.02% on November 12, with a current price of 24.25 CNY per share and a total market capitalization of 13.178 billion CNY, despite a year-to-date increase of 53.77% in stock price [1] Financial Performance - For the period from January to September 2025, Boten Co., Ltd. achieved a revenue of 2.544 billion CNY, representing a year-on-year growth of 19.72%, and a net profit attributable to shareholders of 79.9154 million CNY, which is a significant increase of 138.71% [2] - The company has distributed a total of 1.193 billion CNY in dividends since its A-share listing, with 866 million CNY distributed over the past three years [3] Shareholder Information - As of October 31, 2025, the number of shareholders for Boten Co., Ltd. was 47,800, a decrease of 4.64% from the previous period, while the average number of circulating shares per person increased by 4.86% to 10,469 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 13.2187 million shares to 23.9776 million shares, and Tianhong Medical Innovation A, which reduced its holdings by 458,400 shares to 5.9396 million shares [3]

Core Viewpoint - The stock of Boteng Co., Ltd. has experienced fluctuations, with a year-to-date increase of 52.82% and a recent decline of 15.70% over the past 20 days [1][2] Financial Performance - For the first half of 2025, Boteng Co., Ltd. achieved a revenue of 1.621 billion yuan, representing a year-on-year growth of 19.88% - The net profit attributable to shareholders was 27.0595 million yuan, showing a significant increase of 115.91% year-on-year [2] Shareholder Information - As of October 10, 2025, the number of shareholders for Boteng Co., Ltd. was 50,100, a decrease of 2.75% from the previous period - The average number of circulating shares per shareholder increased by 2.83% to 9,983 shares [2] Dividend Distribution - Since its A-share listing, Boteng Co., Ltd. has distributed a total of 1.193 billion yuan in dividends, with 866 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited, which increased its holdings by 2.3886 million shares to 10.7589 million shares - Tianhong Medical Innovation A reduced its holdings by 513,900 shares to 6.398 million shares, while Southern CSI 1000 ETF entered the top ten shareholders with 3.0218 million shares [3]

Core Insights - On October 20, 2023, Boteng Co., Ltd. saw a stock price increase of 2.59% with a trading volume of 336 million yuan [1] - The company reported a financing buy-in amount of 37.97 million yuan and a net financing buy of 642.37 thousand yuan on the same day [1][2] - As of October 20, the total margin balance for Boteng Co., Ltd. was 501 million yuan, representing 3.73% of its market capitalization [1] Financing and Margin Trading - On October 20, the financing buy-in for Boteng Co., Ltd. was 37.97 million yuan, with a current financing balance of 500 million yuan, which is above the 80th percentile of the past year [1] - The company had a margin repayment of 800 shares and a margin sell of 600 shares, with a margin balance of 686.3 thousand yuan, indicating a low level compared to the past year [1] Business Performance - For the first half of 2025, Boteng Co., Ltd. achieved a revenue of 1.621 billion yuan, marking a year-on-year growth of 19.88% [2] - The net profit attributable to shareholders for the same period was 27.06 million yuan, reflecting a significant year-on-year increase of 115.91% [2] Shareholder Information - As of October 10, 2023, the number of shareholders for Boteng Co., Ltd. was 50,100, a decrease of 2.75% from the previous period [2] - The average number of circulating shares per shareholder increased by 2.83% to 9,983 shares [2] Dividend Distribution - Since its A-share listing, Boteng Co., Ltd. has distributed a total of 1.193 billion yuan in dividends, with 866 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the fifth-largest circulating shareholder, holding 10.7589 million shares, an increase of 2.3886 million shares from the previous period [3] - Tianhong Medical Innovation A was the sixth-largest circulating shareholder, holding 6.398 million shares, a decrease of 513.9 thousand shares [3] - New institutional shareholders included Southern CSI 1000 ETF, which held 3.0218 million shares [3]

Core Insights - The stock price of Boteng Co., Ltd. decreased by 2.03% on September 12, trading at 25.06 CNY per share with a market capitalization of 13.669 billion CNY [1] - The company has seen a year-to-date stock price increase of 58.91%, but a recent decline of 3.24% over the last five trading days [1] Financial Performance - For the first half of 2025, Boteng Co., Ltd. reported a revenue of 1.621 billion CNY, representing a year-on-year growth of 19.88%, and a net profit attributable to shareholders of 27.0595 million CNY, which is a significant increase of 115.91% year-on-year [2] - Cumulatively, the company has distributed 1.193 billion CNY in dividends since its A-share listing, with 866 million CNY distributed over the last three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders for Boteng Co., Ltd. was 52,700, a decrease of 0.75% from the previous period, with an average of 9,502 circulating shares per shareholder, an increase of 0.75% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Tianhong Medical Innovation A, with notable changes in their holdings [3] Business Overview - Boteng Co., Ltd. specializes in CDMO services for chemical raw materials, chemical formulations, and biological CDMO services, including gene and cell therapies [1] - The company's revenue composition includes 66.81% from late-stage clinical and commercialization, 25.76% from early-stage clinical, and 7.11% from emerging businesses [1] Market Position - The company is classified under the pharmaceutical and biological industry, specifically in medical service and medical research outsourcing [1] - Boteng Co., Ltd. is associated with several concepts including CRO, cancer treatment, innovative drugs, and biomedicine [1]